Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 May 18.

Published in final edited form as: Vaccine. 2009 Apr 3;27(23):3045–3052. doi: 10.1016/j.vaccine.2009.03.026

Table 4.

Cytokine/Chemokine Production in Mice Treated with TLR Agonists During RSV Infection

		Day 4 pi				Day 7 pi
Strain	Treatment	IL-10	IFN-γ	MIP-1α	MIP-1β	IL-10	IFN-γ	MIP-1α	MIP-1β
BALB/c	PBS	4 ± 5	59 ± 86	8 ± 14	100 ± 78	6 ± 7	98 ± 56	286 ± 102	785 ± 365
	CpG	87 ± 53 ^a	133 ± 139	710 ± 256 ^a	1623 ± 456 ^a	5 ± 7	295 ± 34 ^a	676 ± 145 ^a	1015 ± 160
	3M-012	ND^b	309 ± 237	86 ± 71	456 ± 193	ND^b	364 ± 95 ^a	401 ± 172	1082.2 ± 213.4
A/J	PBS	ND^b	ND^b	ND^b	63 ± 113	ND^b	71 ± 75	19 ± 22	117 ± 55
	CpG	39 ± 11 ^a	72 ± 34 ^a	256 ± 64 ^a	798 ± 143 ^a	2 ± 1	519 ± 207 ^a	312 ± 118 ^a	658 ± 216 ^a
	3M-012	11 ± 3	18.7 ± 7.4	22 ± 22	154 ± 38	ND^b	125 ± 53	113± 47	326 ± 106
FVB	PBS	ND^b	14.7 ± 10.6	43 ± 42	188 ± 92	ND^b	22 ± 7	125 ± 34	341 ± 57
	CpG	140 ± 61 ^a	103.4 ± 59.0 ^a	952 ± 158 ^a	2344 ± 249 ^a	22 ± 7 ^a	182 ± 81 ^a	680 ± 110 ^a	1340 ± 170 ^a
	3M-012	12 ± 5	24 ± 22	54 ± 22	183 ± 30	ND^b	51 ± 23	113 ± 46	302 ± 82

^a

Statistically significant relative to PBS-treated mice of the same strain, p<0.05.

^b

ND = not detected